CHINA FOCUS @SAN FRANCISCO 2020

GRAND HYATT SAN FRANCISCO – Ballroom Level
345 Stockton St, San Francisco, CA, U.S.

JAN 12
2020

:ORGANIZER

: PLATINUM SPONSOR

: GOLD SPONSOR

DIRECTION

- VIP PARTNERING
- OFFICE
- 1-ON-1 PARTNERING
- PLENARY SESSION (with simultaneous interpretation)
- COMPANY PRESENTATION
- EXHIBITION
- BREAKOUT B
- BREAKOUT A

QUICK GUIDE



EXHIBITION

8:00-19:00



Exhibitor List

1. Zhimeng Biopharma (Shanghai)
2. Jiangsu Industrial Technology Research Institute (JITRI)
3. iHEAR Medical, Inc.
4. BioKatalyst
5. Echo lab
6. Nanjing Jiangbei New Area
7. China Focus@ Europe Paris
8. Bayer
10. Gloria Biosciences
12. Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

CHINA FOCUS

EVENT CONTENTS

PLENARY SESSION AGENDA

TIME	TOPIC
7:00-8:00	**Check in and free networking**
8:00-8:20	**Opening Remarks** Xinxin Li, VP of Strategic Partnerships, MyBioGate
8:20-9:20	**Keynote speeches** Discovering HER2, Herceptin – And Opportunities for Future Breakthroughs through Global-American-Chinese Research Collaboration – 2019 Lasker Award winner; Herceptin inventor, H. Michael Shepard Global life science and healthcare investment and finance 2019 – Katherine Andersen, Head of Life Science & Healthcare, Silicon Valley Bank
9:20-10:50	**Chinese companies' road to world-class corporations** **Moderator:** Helen Chen – Greater China Managing Partner, L.E.K. Consulting Internationalization of Chinese companies in Healthcare – Dajian Cai, GTJA Investment Group Phoenix Reborn--Innovative R&D Strategy and Plan of Gloria Biosciences – Helena Meng, VP and CMO, Gloria Biosciences Rising China Biotech: The CStone Story – Shirley Zhao, CStone Pharma Opportunities and challenges in China healthcare market – Helen Chen, L.E.K. Consulting **Fireside chat** Dajian Cai – Chairman, GTJA Investment Group Shirley Zhao – Great China General Manager & Head of Commercial, CStone Pharma Austin Zhu – President of Gloria Pharmaceuticals, General Manager of Gloria Biosciences
10:50-11:40	**Panel 1 – New landscape and trends of investment in life science & healthcare** **Moderator:** Kim Nearing – Venture Partner, BVCF Management, ltd. **Panelists:** James Huang – Founding Partner, Panacea Venture; Managing Partner, KPCB China Amy Tang – Venture Partner, Qiming Venture Partners Bo Liu – Executive VP & Managing Director- Healthcare Investments, CDIB Capital John Zhu – Partner, 6 Dimensions Capital Mark Tang – Managing Director, Good Health Capital Wendy Pan – Partner, Goodwin LLP
11:50-12:30	**Medical device elevator pitch (Company Info on page 9)**
12:30-13:30	**Lunch Break**
13:30-14:15	**Panel 2 – China market needs for medical devices** **Moderator:** Tianji Zhu, VP, CD Capital **Panelists:** Yonghui Shi – Managing Director, Metronic China Fund Adam Zhao – Partner, Anlong Fund Yu Fang – Partner, 3E Bioventures Capital Drake Yu – Founding Partner, LYFE Capital
14:15-15:00	**Fireside Chat – MNCs' strategies to meet new opportunities and challenges in the China market** **Moderator:** Dennis Purcell – Founder and Senior Advisor, Aisling Capital **Guest speakers:** Wei Jiang – Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC; President, Bayer Group Greater China
15:00-15:15	**Introduction of Nanjing Jiangbei New Area** Chanmei Chen – Executive Deputy Director of Nanjing Municipal Jiangbei New Area Administrative Committee
15:15-15:30	**Break**
15:30-16:15	**Panel 3 – Market needs and access in China (Panel Partner: BioKatalyst)** **Moderator:** Paul Zhang – Partner, Bluestar Bioadvisors LLC; President, BioKatalyst **Panelists:** Bing Yuan – Chief Business Officer, Cstone Pharmaceuticals Zhimin Jimmy Zhang – Venture Partner, Lilly Asia Ventures Derek Small - Founding General Manager, Assembly Biosciences Research & Development Co. Shanghai Jonathan Wang – Senior VP Head, Business Development, Zai Lab Lingyun Dong – General Manager, Yeedozencom Science & Technology
16:15-17:00	**Panel 4 – Chinese pharma' s overseas outreach and collaboration** **Moderator:** Jun Bao – President and CEO, Impact Therapeutics **Panelists:** Geffrey Gao – Executive VP/Deputy GM, Harbin Pharmaceutical Group Larry Cai – Executive Director of BD, Fosun pharma Xiangbin Xu – President, Simcere Innovation Center Brad Loncar – CEO, Loncar Investments Lu Cao - US Head of Corporate Banking for Chinese Multinationals, J.P. Morgan

SPEAKER

KEYNOTE SPEECH

Discovering HER2, Herceptin – And Opportunities for Future Breakthroughs through Global-American-Chinese Research Collaboration

H. Michael Shepard

2019 Lasker Award winner;
Herceptin inventor

Lasker Award-Winning Bio-Oncologist and life sciences researcher Dr. H. Michael Shepard is best known for his groundbreaking work leading the team identifying the toxic HER2 gene, and its role in the most deadly forms of breast cancer – and then inventing the breakthrough drug “Herceptin” to block it (treating over 2.3 million people to date). Dr. Shepard will share with the China Focus@San Francisco event the research path taken to discover and launch “Herceptin” ; his current Cancer and Autoimmune Disease research; and his interest/support regarding increasing opportunities for global research teams – particularly between the United States and China – to collaborate and address the world’ s greatest health challenges.

Global life science and healthcare investment and finance 2019

Katherine Andersen

Head of Life Science &
Healthcare Relationship Banking
Silicon Valley Bank
China Focus insight partner:
Silicon Valley Bank

Katherine Andersen serves as Head of Life Science & Healthcare Relationship Banking at SVB. She also serves on the Board of Directors for SVB's Joint Venture in China, SPD Silicon Valley Bank. Prior to SVB, Katherine was a Senior Vice President for Wells Fargo Bank leading the Life Sciences business development and relationship management efforts for the New England region. Before that, she was a Director at Wells Fargo Capital Finance focused on front-end business development and underwriting of structured loans. Prior to Wells, she held various positions across mergers and acquisitions, finance, equity derivatives, audit, and management while at Affiliated Managers Group, Merrill Lynch, GE Corporate Audit Staff and GE Capital.

Away from work, Katherine serves on the Finance Advisory Board for Virginia Tech, the Board of Directors for WEST (Women in the Enterprise of Science & Technology), and as Chairperson for the American Cancer Society’ s Hope Lodge Corporate Council.

SPECIAL TALK

Chinese companies’ road to world-class corporations

Helen Chen

Helen Chen, Greater China
Managing Partner, L.E.K.
Consulting

Helen is a Greater China Managing Partner of L.E.K. based in Shanghai. She was a member of L.E.K.’ s Global Leadership Team from 2012 to 2016. Helen is also head of L.E.K.’ s China and Asia Biopharmaceuticals & Life Sciences practice and a Director of the firm’ s Asia-Pacific Life Sciences Centre of Excellence. She has extensive case work and industry experience covering the full biopharmaceutical and medical devices value chain.

Helen has 30 years of consulting and industry experience in the U.S. and Asia markets and has resided in China since 2000. She helps companies expand their presence in China and leverages China’ s resources to improve their global businesses. Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China.

Dajian Cai

Chairman and Founder
Shenzhen GTJA Investment Group

Dr. Cai is among the “School of 1992” - iconic Chinese entrepreneurs and investors rising from the Era of Economic Reform. With a Ph.D. in Finance and EMBA at China Eur sp eech by Deng Xiaoping during his inspection in the south in 1992, Mr. Cai resigned from his job and started his career in Shenzhen, making himself one of the earliest enlighteners and explorers of venture capital as a member of the renowned JUN’ AN SECURITIES and later GUOTAI JUN’ AN SECURITIES , and produced the most famous IPO in that time.
GIG, led by Dr. Cai, is one of the top healthcare investment institutions in China and has earned reputation in both business innovation and investment philosophy.

Shirley Zhao

M.D. & MBA
Greater China General Manager and Head of Commercial Operations, CStone

A seasoned leader with a proven track record of over 26 years working at leading multinational pharmaceutical companies; 10 years of Country Manager experience at Bristol-Myers Squibb (BMS), Allergan, and Genzyme in China; built Allergan China operation from a small base to the second largest globally;
Led successful launches of numerous brands and established them as market leaders in China, including Opdivo®, Botox®, Alimta®, Gemzar®, Taxol® and Juvederm®;
Devoted 15 years to the oncology field as VP & Head of Oncology BU, Eli Lilly China, and as Head of Marketing, Oncology at BMS China;
Started her career as an OB-GYN Doctor and got her M.D. degree from Tongji University School of Medicine in China; received her MBA from the University of Leicester, United Kingdom.

Austin Zhu

Chairman of Gloria Pharmaceuticals
General Manager of Gloria Biosciences

Austin Zhu, Medical degree, doctor background, the founder of Gloria Pharmaceuticals which is an A-share listed company. He has been rooted in the pharmaceutical industry for more than 30 years. With his great and strong leadership, in 2015, Gloria Biosciences was founded which focuses on innovative biological medicine for oncology in China.

Helena Meng

Vice President, Chief Medical Officer of Gloria Biosciences

Trained as both a medical doctor (in China) and molecular geneticist (in US), Dr. Meng has 20+ years of experience of drug development and drug lifecycle management. She understands the need and practice for both doctors and molecular geneticists, and how genetic translational research can be applied to modern drug development. She had worked in medical functions for ~10 years in several multi-national companies, like Pfizer and Bristol-Meyers-Squibb, successfully managed clinical trials of different phases and NDA application with regulatory agencies, and also led an innovative medical program working with government providing a leap in improving chronic disease management in China.

FIRESIDE CHAT

MNCs' strategies to meet new opportunities and challenges in the China market

Dennis Purcell (Moderator)

Founder and Senior Advisor
Aisling Capital

Mr. Purcell is the original Founder of Aisling Capital LLC. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

Wei Jiang

Executive Vice President and President
Bayer Pharmaceuticals Region China & APAC
President
Bayer Group Greater China

Mr. Jiang is currently the EVP, Member of Executive Committee, responsible for the Bayer Pharmaceuticals business in Region China & APAC and for the Bayer Group in Greater China. Mr. Jiang has over twenty years of extensive Sales & Marketing and general management experience within the Healthcare industry across broad geographies in the US, China and APAC region. Prior to his senior regional business leadership roles at Bayer, he held multiple senior management positions with AstraZeneca (AZ) in China and APAC region, Guidant Corporation in China and Eli Lilly in the US and in China. Mr. Jiang has a BBA in Business Administration & Finance from Campbell University, North Carolina, USA and a MA in Economics, Indiana State University, Indiana, USA.

PANEL 1

New landscape and trends of investment in life science & healthcare

Kim Nearing (Moderator)

Venture Partner,
BVCF Management, ltd.;
Sr. Vice President,
Amato and Partners;
Board of directors,
BayHelix

Kimberly Nearing has over 20 years of international life sciences experience, including in financial services, operations (Amgen, Merck, IBM Healthcare) and consulting. Kim recently joined BVCF as Venture Partner and Amato and Partners (capital market advisory firm) as Sr. Vice President, along with being elected to BayHelix' s Board of Directors. Previously, for over a decade, she was Managing Director, Head of Life Sciences at the Cedrus Group, a Hong Kong-based global boutique investment firm, focused on driving international business and investment between the U.S., Europe, Greater China, and broader Asia regions. She is also an Independent Director, MaveriX Oncology (Silicon Valley), and Board of Directors/Executive Committee Member, RVF (foundation in Washington D.C.). * Master of Science with Honors from Harvard University and a Bachelor of Arts with Distinction from the University of Michigan.

James Huang

Founding Partner,
Panacea Venture;
Managing Partner,
KPCB China

Prior to creating Panacea Venture, James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm' s life science investment. His main investment interests are innovation around China' s growing healthcare markets and helping entrepreneurs build companies. Before KPCB China, James was a managing partner at Vivo Ventures. James has made more than 15 investments in China since 2007.

Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he held various senior positions in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).

James is Chairman of Board at Kindstar Global and JHL Biotech, and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, and XW Laboratory.

Amy Tang

Venture Partner,
Qiming Venture
Partners

Ms. Amy Tang is a Venture Partner at Qiming Venture Partners. She previously worked in Morningside Ventures for 13 years (2002~2015) in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.

Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years.

Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB).

Bo Liu

Executive VP &
Managing Director-
Healthcare Investments,
CDIB Capital

Robert is Managing Director of healthcare investments at CDIB Capital Group. Prior to joining CDIB, he was Principal, Venture Investments at Johnson & Johnson Development Corporation (JJDC), responsible for the venture and private equity investments in life science and healthcare in Asia Pacific region. Prior to JJDC, Robert served as Director of Business Development & Strategy of Greater China at GlaxoSmithKline, and worked in the Global Corporate Development & Strategy team of Charles River Laboratories, in Boston USA. Robert has executed over $3 billion M&A and investment transactions in the US, Europe and Asia.

Robert holds a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago Booth School of Business and a Master Degree in Medicine (7-year program) from Tongji Medical University. Robert also received the residency training in Urology at Union Hospital, Wuhan China.

John Zhu

Partner,
6 Dimensions Capital

Dr. John Zhu, Partner of 6Dimensions Capital. Prior to that, he worked for Wuxi Ventures, Greenwoods Asset, Applied Biosystems, etc. Dr. Zhu has over 15 years of experience in health care industry. He has led 20+ private equity investments, including CStone Pharma, Phoenix Healthcare Group, BGI, Gan&Lee, etc. He earned his MBA from University of California at Berkeley and PhD from University of Massachusetts Medical Center.

Mark Tang
Managing Director,
Good Health Capital

Mark Tang is a managing director and a founding partner of Good Health Capital in New York, which manages healthcare PE funds. A veteran Chinese biotech investment banker from mainland China, Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He was a biotech director for Rutgers Business School and a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of The Essential Biotech Investment Handbook, which is published both in English and Chinese. Mark is currently on the boards of two US biotech companies. He holds degrees from NYU Stern and the Harvard School of Public Health.

Wendy Pan
Partner,
Goodwin LLP

WENSENG “WENDY” PAN leads Goodwin Procter’ s life sciences practices in Asia. A renowned lawyer and deal maker in the US/Chinese life sciences communities, she regularly advises Chinese, U.S. and multinational life sciences and technology companies, as well as venture and private equity firms in structuring and negotiating mergers and acquisitions, private and public financings, and complex IP-based transactions. Her deep legal experiences, coupled with her unparalleled understanding about the businesses and technologies and her pragmatic approach have made her the trusted advisor and go to person in the US-China life sciences communities. Wendy has been ranked by Chambers, recognized by IFLR1000 as a leading lawyer for M&A, Who’ s Who Legal: Life Sciences (Transactional) and is a recipient of the Legal Services Award by China M&A Association. She is a member of the Board of Directors of The BayHelix Group. Wendy obtained her JD and PhD (in chemistry) from Columbia University.

PANEL 2 China market needs for medical devices

Tianji Zhu (Moderator)
VP
CD Capital

Adam Zhao
Partner, Anlong Fund

Yonghui Shi
Managing Director,
Metronic China Fund

Drake Yu
Founding Partner,
LYFE Capital

Yu Fang
Partner
3E Bioventures Capital

Dr. Francine Fang has over 20 years’ experience in healthcare industry and venture investment. She is a founding partner of 3E Bioventures Capital, a healthcare-focused venture investment firm actively investing in worldwide new drugs and innovative medical devices and diagnostics.
Prior to 3E Bioventures, Francine worked as a Venture Partner at Fidelity Growth Partners Asia (FGPA) and Tuspark Venture, and led healthcare investment transactions including Eyebright, Cytoville (Cytek), Shenogen pharma, etc. She also spent 10 years working in US as a group leader in R&D at BD Biosciences, a multinational medical device company, and Clonetech, a US biotech startup eventually acquired by BD Biosciences.
Francine received her Ph.D. degree in Physiology and Neuroscience from University of Medicine and Dentistry of New Jersey, and M.D. degree in Medicine from Capital Institute of Medicine in China.

Introduction of Nanjing Jiangbei New Area

Ms. Chanmei Chen
Executive Deputy Director of
Nanjing Municipal Jiangbei New Area Administrative Committee

PANEL 3 Market needs and access in China (Panel Partner: BioKatalyst)

Paul Zhang (Moderator)
Partner
Bluestar Bioadvisors LLC;
President
BioKatalyst

Paul is a senior leader in the life sciences consulting industry. He was a Partner at Easton Associates LLC, a Managing Director at Navigant, which acquired Easton, and ClearView Healthcare Partners. Paul has led over 800 engagements serving clients from startups to Top 10 pharmaceutical companies, integrating scientific acumen with commercial industry know-how to generate experience-based, actionable advice to global client management teams. He is also a preeminent expert on the rapidly evolving China market, having built a consulting team in Shanghai and Beijing over the last 10 years. Prior to starting his consulting career, Paul spent 6 years in the pharmaceutical industry in preclinical research and pipeline strategy roles at BMS, Knoll Pharmaceuticals, and Pharmacia. Paul holds an MBA degree from Cornell University' s Johnson School and a M.S. degree in Molecular Biology from Rutgers University.

Bing Yuan
Chief Business Officer,
Cstone Pharmaceuticals

Dr. Yuan has over 20 years of experience in oncology global BD&L, strategic marketing, management, and scientific research. Prior to CStone, Dr. Yuan was the Executive Director and Global Lead, Oncology BD&L at MSD, playing a key role in the success of 9 global oncology brands, led world-wide oncology BD and successfully achieved 34 deals in immune-oncology. Before MSD, Dr. Yuan was the Executive Director and Global Head of life cycle strategy at Novartis oncology.
Dr. Yuan obtained his Ph.D. from Columbia University, an MBA from Cornell University, and B.S. from Nanjing University.

Jimmy Zhang
Venture Partner,
Lilly Asia Ventures

Dr. Jimmy Zhang is a Venture Partner at LAV (Lilly Asian Ventures). He was former Vice President (global level), Transactions, Johnson & Johnson Innovation. He led the transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, as well as fund relationship and partnership in the region. Before joining J&J, Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team. He was in charge of Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. He was also a Board Director of BeiGene (Beijing) Co, Ltd. (NASDAQ: BGNE) and an Advisor Board member of Cenova Ventures.

Derek Small

Founding General Manager,
Assembly Biosciences
Research & Development
Co. Shanghai

Derek is a member of the Board of Directors and serves as a senior advisor at Assembly Bio. He is a co-founder of Assembly and served as President and CEO from 2015 to 2019. Currently, Mr. Small is Managing Director of Luson Bioventures, a biopharmaceutical venture creation firm that he founded in 2007. Previously, he served as a founding director, President and CEO of Naurex, which was acquired by Allergan in 2015. Naurex's preclinical programs formed the basis for a spinout, Aptinyx, which completed an IPO in 2018. He also served as a founding director, President and Chief Executive Officer of Coferon and Assembly Pharmaceuticals, and has helped to launch and advance several other biotechnology companies.

Jonathan Wang

Senior VP Head, Business
Development,
Zai Lab

Jonathan Wang is our Senior Vice President, Head of Business Development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking.
Mr. Wang holds a Master of Business Administration in healthcare management from Wharton Business School.

Lingyun Dong

General Manager
Beijing YEEDOZENCOM
Healthcare Science &
Technology Co., Ltd.

Mr. Dong successively served as the cadre of the evaluation management and coordination department and vice minister of the information department of the CDE in NMPA.
Participated in the drafting and revision of various registration regulations including the current ones, and was one of the main designers of China's drug evaluation system and review process.

PANEL 4 Chinese pharma's overseas outreach and collaboration

Jun Bao (Moderator)

President and CEO,
Impact Therapeutics

Dr. Jun Bao has over 20 years of combined business and R&D experiences. He is highly experienced in the field of new drug R&D, tech transfer, licensing and business development, M&A, venture investment, company start-up and operation. He currently serves as President & CEO of Impact Therapeutics. Prior to Impact, he served as Senior Vice President and Chief Business Officer at Shenogen Pharma Group, where he was also a member of board of directors as well as acting Chief Financial Officer. Before joining Shenogen, Dr. Bao was Director, Worldwide Business Development, Head of China at GlaxoSmithKline (GSK). Prior to GSK, he worked at Onyx Pharmaceuticals, ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities, as well as a finance manager in Procter & Gamble based in Cincinnati. He received a BS in Microbiology from Shandong University and a PhD in Neuroscience from University of Kansas. Dr. Bao completed his postdoctoral fellowship in Johns Hopkins University. In addition, he received an MBA in Finance from University of Chicago. He has authored/co-authored more than 30 research publications and co-founded three start-up biotech companies. Dr. Bao serves as a board member of BayHelix.

Geffrey Gao
Executive VP/Deputy GM,
Harbin Pharmaceutical Group

Dr. Lei Gao has a unique background with a combination of biomedical research, management consulting, investment banking, financial investment, and M&A. Originally trained as a scientist, Lei earned his Ph.D. in Pharmacology at Brown University and received post-doctoral training in Neuroscience at the University of Pennsylvania.
In 2015, Lei came back to China and joined Tasly Pharma/Tasly Capital as the head of international investment. Over a period of 3 years, he successfully consummated transactions in all major markets including the U.S., China, Europe, Canada, and Australia.
In September 2018, Lei joined Harbin Pharma as an EVP/Deputy GM responsible for strategy, BD, investment, and M&A.

Larry Cai
Executive Director of BD,
Fosun pharma

Larry Cai is Executive Director of Business Development and Licensing at Fosun Pharma USA, based in Boston MA. He has more than 20 years of experience in business development and research and development in life science industry. Larry is responsible in search and evaluation of innovative assets, ranging from early stage technology platform to late clinical stage therapeutics. He is also responsible for divesture of ANDAs at Fosun. In addition, Larry is involved in setting up new cutting-edge biotech startup companies. Prior to Fosun, he was head of business development and public affairs at Qilu Pharmaceuticals, helped establish Qilu Boston Innovation Center (QBIC). Larry completed his undergraduate and graduate degrees in the US, after transferring from Peking University. He was involved in the volunteer based New England Sino-American pharmaceutical Professionals Association (SAPA-NE), serving as its president from 2017-2018.

Xiangbin Xu
President,
Simcere Innovation Center

Dr. Xu is one of the founders of Simcere innovation, Inc. and responsible for the establishment of Simcere Innovation in Boston, and development and implementation of Simcere Innovation' s strategies covering operation models, drug discovery and early development, and external innovation. He also works closely with Simcere' s management team for the company's discovery and early development R&D strategies, and with global BD for external opportunities for collaboration, in-licensing, or investment, etc.
Dr. Xu has 15+ year experience in the top pharmaceutical industries and academic institute. He led and participated in 30+ R&D discovery and early development projects of cell therapies, biologics and small molecule drugs, including several compounds are at IND and clinical development stages.

Brad Loncar
CEO,
Loncar Investments

Brad Loncar is an independent biotech investor and analyst, and has managed a biotech-focused family office since 2008. Through Loncar Investments LLC, he uses his research of biotech companies and technologies to develop thematic biotech investment indexes. The Loncar Cancer Immunotherapy Index was launched in March of 2015. It is the only of its kind and consists of 30 companies leading the way in the emerging field of cancer immunotherapy. Brad previously worked at Franklin Templeton Investments and served in a Senior Advisor role at the U.S. Department of the Treasury. He is one of the most followed biotech commentators on social media and writes biotech commentary at www.LoncarBlog.com.

Lu Cao
US Head of Corporate Banking for Chinese Multinationals, J.P. Morgan

Lu Cao is an Executive Director in the Corporate and Investment Bank providing corporate banking relationship coverage for the North American business of large foreign multinational companies. She leads the China Desk effort at the Global Corporate Bank in North America focusing on corporates with global headquarters in Greater China across a number of sectors including TMT, transportation/shipping, natural resources, consumer, healthcare, and other diversified industries.

Lu has been with J.P. Morgan for more than 16 years. Before joining the Global Corporate Bank, Lu was with J.P. Morgan' s Private Bank in Hong Kong from 2008-2010 providing private banking relationship coverage for ultra high net worth clients in Greater China, prior to which she worked at the Investment Bank in New York City, and began her career with the firm' s investment banking analyst program. Lu has a Bachelor of Arts degree in Economics and International Relations from Colgate University.

BREAKOUT A AGENDA

TIME	TOPIC
	Morning: AI and Digital health
11:00-12:00	**AI and novel therapeutic solutions** Moderator: Echo Hindle-Yang – CEO at M.S.Q. Ventures Panelists: Hainian Zeng – CEO, Silexon AI Technology Alan Jiang – CSO, XtalPi Andrew Radin – CEO, twoXAR Guo-liang Yu – Global CEO, Apollomics Inc Daniel Teper – Co-Founder, Chairman & CEO, CYTOVIA Therapeutics
	Afternoon: Session sponsored by YEEDOZENCOM
13:30-14:00	**Interpretation of the Latest Pharmaceutical Administration Law of the People's Republic of China and Provisions for Drug Registration.** Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
14:00-14:15	**Introduction of YEEDOZENCOM** Lingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
14:15-15:00	**Route Exploration of the Drug Marketing Authorization in China** Moderator: Lingyun Dong – General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd. Panelists: Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd. Xiumin Huo – Professor of YEEHONG Business School Zhi Xiao – Managing Director, SDIC Fund Zhenyu Li – Business Development Director of LUNAN PHARMACEUTICAL GROUP CORP.
15:00-15:30	**Tea Break**
15:30-16:00	**Q&A for Medicine Launching Regulations in China Market** Zhen Chen – Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

SPONSORED BY YEEDOZENCOM

亦度正康
YEEDOZENCOM

SPEAKER

MORNING: AI AND DIGITAL HEALTH

AI and novel therapeutic solutions

Echo Hindle-Yang (Moderator)
CEO
M.S.Q. Ventures

Echo is on a mission to make technology accessible by bridging the gap between western companies and Chinese corporations and investors. She has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, Lenovo and J&J. In recent years, making the global movement of the healthcare industry has been her focus. She has been advising hundreds of western pharmaceutical and medical devices companies on advancing their success in China including subsidiaries of Novartis, Daichi, and other top global healthcare companies.
Echo holds an MBA from Duke University and the FINRA Series 7, 63 and 79 securities licenses. She is currently serving on DukeNY Board.

Hainian Zeng
CEO,
Silexon AI Technology

Hai-Nian is CEO of Silexon AI Technology, an open AI platform aimed to empower drug discovery and life science research. Before joining Silexon, Hai-Nian was in charge of innovative biopharmaceutical investment and management as Vice President at PingAn Ventures， with portfolio including Tmunity, NextCure, Hua Medicine, KBP, XGENE, Rani, Prenetics and etc.. Prior to that, Hai-Nian served as Senior BD Manager for Sinopharm Holding, with responsibilities of creating cross-border collaboration, conducting licensing deals and acquisitions in addition to strategic planning for the whole industrial sector. Hai-Nian was also adjunct reviewer/inspector for Shanghai FDA Center for Certification and Evaluation and deputy GM for Sinopharm Wonder Dream. Hai-Nian got his Master in Bioscience Regulatory Affairs from Johns Hopkins, Master in Plant Biology from NC State, and Bachelor of Life Sciences from Fudan University.

Alan Jiang
CSO,
XtalPi

Dr. Jiang as Chief Strategy Officer, Board Director of XtalPi, bears primary responsibility for company's strategy development. He joined XtalPi in 2015 bringing over fifteen years of scientific and management experience, most of it gained in positions of increasing responsibility at Sanofi-Genzyme. He was the director of Asia R&D Strategy and responsible for the development of Asia/China R&D strategy and led cross-functional R&D external collaborations and projects in Asia. Dr. Jiang received his medical degree and doctorate followed by post-doctoral research in hematology and oncology at Harvard Medical School.

Andrew Radin
CEO,
twoXAR

Andrew A. Radin is cofounder and CEO of twoXAR, a pharmaceutical company dedicated to drug discovery and development by harnessing the power of Artificial Intelligence to transform the traditional R&D approach. Prior to twoXAR, Radin held CTO roles at several early-stage companies. He studied biomedical informatics at Stanford University’ s SCPD graduate program and holds MS and BS degrees in computer science from Rochester Institute of Technology.

AFTERNOON: SESSION SPONSORED BY YEEDOZENCOM

亦度正康
YEEDOZENCOM

Lingyun Dong
General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

Zhen Chen
Chief Scientist & Deputy General Manager of Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.

Xiumin Huo
Professor of YEEHONG Business School

Zhi Xiao
Managing Director, SDIC Fund

Zhenyu Li
Business Development Director of LUNAN PHARMACEUTICAL GROUP CORP.

BREAKOUT B AGENDA

TIME	TOPIC

Morning: Cell and Gene therapy

10:00-11:00 **Technological bottlenecks and breakthroughs in cell and gene therapy**

Moderator: Alain Vertès – Managing Director, NxR Biotechnologies GmbH

Panelists:

Zhenhua Wu – CEO, Exegenesis Bio

Lynnet Koh – CEO, Targazyme

Jason Slingby – CBO, Oxford Biomedica

Frank Zhang – CEO, GenScript

Innovation in Jiangsu

11:10-11:40 **Jiangsu Industrial Technology Research Institute (JITRI) Introduction**

Paul E. Burrows - Vice President of Jiangsu Industrial Technology Research Institute

11:40-11:50 **JITRI Southern California Innovation Center Introduction**

Calvin Chen - CEO of CrossLinkBio,Inc.

12:00-13:00 **Lunch networking with Jiangsu companies and investors**

13:00-13:20 **Jiangsu Innovative Healthcare Companies Introduction**

13:30-14:30 **Projects Partnering**

14:30-18:00 **Medical device company presentation**

14:30 - 15:40	15:50 - 16:50	17:00 - 17:50
TomoWave Laboratories	PhysioCue, Inc.	Abilitech Medical, Inc.
Brainstorm Medical Inc.	PhotoniCare, Inc.	Aevumed Inc.
Fibralign Corporation	Replication Medical, Inc.	Advance Scanners, Inc.
Yolia Health	Cosm Medical	TriReme Medical
Pacific Diabetes Technologies	Nanochon, LLc.	iHear Medical, Inc.
ThermopeutiX, Inc.	Eyedetec Medical, Inc.	
Vave Health, Inc.		

SPONSORED BY JITRI

JITRI
JIANGSU INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

SPEAKER

MORNING: CELL AND GENE THERAPY

Technological bottlenecks and breakthroughs in cell and gene therapy

Alain Vert è s (Moderator)
Managing Director,
NxR Biotechnologies GmbH

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm founded in 2011 and based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Active in alliance management for Mesoblast, prior to NxR Biotechnologies Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, as well as at Roche where he notably led through an external innovation partnering function the global cell therapeutics strategy and implementation team from 2007-2010.

Zhenhua Wu
CEO,
Exegenesis Bio

Dr. Zhenhua Wu is a senior R&D leader with more than 20 years' experience and a deep understanding of pharmaceutical R&D value chain, and extensive R&D experience in small molecule, vaccine and cell and gene therapy. Dr. Wu is the founder and CEO of Exegenesis Bio Inc., a start-up company focusing on the development of innovative cell and gene therapies for high-need patients. Prior to this, he was the CEO of NeuExcell Therapeutics. Previously he was the Vice President, Head of Preclinical Development of United Neuroscience, served as a director of neuroscience therapeutic area at GlaxoSmithKline, and had worked in various functional areas in Merck & Co. for ten years and served as a global externalization lead.
Zhenhua is also a recipient of Hugh Davson Distinguished Award in Neurovascular Biology. Zhenhua Wu served as the President (2016-2018) of Sino-American Pharmaceutical Professional Association – Great Philadelphia (SAPA-GP).

Lynnet Koh
CEO,
Targazyme

Lynnet has successfully led the research, development, manufacturing of Targazyme' s immuno-oncology drugs from idea stage to completion of phase 2 clinical trials and Phase 3 readiness. Key milestones and awards received: FDA Phase 3 Special Protocol Assessment, multiple FDA Orphan Drug Designations, worldwide patents. Major validation received: $30MM+ of medical grants with leading clinical collaborators, publications in Blood, Clinical Cancer Research and Nature, collaborations with Astellas, Kyowa Hakko Kirin, leading research centers such as MD Anderson Cancer Center and OMRF.
Lynnet has proven successes with leading game-changing, award-winning technology innovations in the biotech, wireless and internet industries. They include: Targazyme' s novel enzymes with their potential for improving the efficacy, safety and cost of care for cell therapy, the world' s first generation caller ID (AT&T Bell Labs), first generation wireless systems (AT&T Bell Labs); first generation internet-networking voice/video/data infrastructure products.

Jason Slingsby
CBO,
Oxford Biomedica

Jason joined Oxford BioMedica in 2015 and has been Chief Business Officer since 2018. He has 20 years' experience in the biotechnology industry in biologics, vaccines and gene therapy. He has worked in international business development roles at Sosei Co., Ltd, and Intercell AG and was co-founder and CEO of ProtAffin AG, a venture capital backed company in Austria and UK. Jason was awarded a 1st class BA (Hons) in Biochemistry from Magdalen College, Oxford University and also completed an PhD in complex disease genetics from Imperial College London. Jason was awarded an MBA with distinction from London Business School.

Frank Zhang
CEO,
GenScript

Frank Zhang, Ph.D. is the founder, Chairman and CEO of GenScript Biotech Corporation. Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has established global presence across Greater China, North America, Europe and Asia-Pacific regions. GenScript is committed to being the most reliable biotech company in the world to make humans and nature healthier through biotechnology. Frank is a guest author for Annual Review of Biochemistry and the owner of 9 scientific patents. He received his Ph.D. in bio-chemistry from Duke University. During his tenure at Schering-Plough from 1995 to 2002, Frank excelled at drug development in oncology, cardiovascular and central nervous system diseases. He is the first one to successfully clone human geranylgeranyl transferase, an important enzyme in oncology. Because of his p
rominent scientific accomplishments, Frank received Presidential Award from Schering-Plough. Frank also made distinguished academic contributions, he has published over 20 papers in a number of world-renowned scientific journals.

INNOVATION IN JIANGSU

JITRI
JIANGSU INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Paul E. Burrows
Vice President of Jiangsu
Industrial Technology
Research Institute

Calvin Chen
CEO of CrossLinkBio,Inc.

MEDICAL DEVICE ELEVATOR PITCH

Location: Plenary

Time: 11:50 – 12:30

Please click the company name for more information and presentation time at Breakout B.

	COMPANY NAME	CATEGORY	PRESENTER
1	TomoWave Laboratories	Medical Imaging	Alexander Oraevsky, Ph.D.
2	Brainstorm Medical Inc.	Medical Imaging	Alex Triener, M.B.A.
3	Fibralign Corporation	Cardiovascular Intervention	Greg King, M.B.A.
4	Yolia Health	Ophthalmic Devices	Alberto Osio, M.B.A.
5	Pacific Diabetes Technologies	In-Vitro Diagnostics	Robert Cargill, Ph.D.
6	ThermopeutiX, Inc.	Cardiovascular Intervention	Ronald Solar, Ph.D.
7	PhysioCue, Inc.	Cardiovascular Device	Simon Yi, M.S.
8	PhotoniCare, Inc.	Medical Imaging	Ryan Shelton, Ph.D.
9	Replication Medical, Inc.	Orthopedic Device	Ann Prewett, Ph.D.
10	Cosm Medical	Medical Imaging	Derek Sham, M.B.A.
11	Nanochon LLC.	Orthopedic Device	Ben Holmes, Ph.D.
12	Eyedetec Medical, Inc.	Ophthalmic Device	Barry Linder, M.D.
13	Vave Health, Inc.	Medical Imaging	Amin Nikoozadeh, Ph.D.
14	Abilitech Medical, Inc.	Orthopedic Device	Angie Conley
15	Aevumed, Inc.	Orthopedic Device	Saif Khalil, Ph.D.
16	TriReme Medical	Cardiovascular Intervention	Michael Van Zandt, M.B.A.
17	iHear Medical	ENT Device	Adnan Shennib, Ph.D.



TomoWave Laboratories, Inc

www.tomowave.com

Presentation Time at Breakout B: 14:31 – 14:40

Executive summary of your company :

TomoWave Laboratories is a hi-tech company developing proprietary medical imaging devices based on biomedical optoacoustics and laser ultrasound invented by the founder, Dr. Alexander Oraevsky.

Nine years of research and development sponsored by the US Government (NIH) grants resulted in a pipeline of imaging systems and clinical applications. Sales of the first commercial product, Laser Optoacoustic Imaging System, for preclinical research in laboratory animals, started in China in Q3 2019 and the first 2 systems were sold with additional 23 leads. TomoWave subsidiary in China plans to land in Q1 2020. Presently, TomoWave is implementing its Series A investment plan with a strategy for exit through IPO or acquisition by 2024. Full investment required to achieve the exit point value is $15M. The minimal investment is set to $1M to accomplish a logical and tangible milestone of commercial system validation, which can boost the company valuation for further rounds of investment.

Primary indication(s):

Medical diagnostic imaging

Product/technology description:

Optoacoustic tomography is the fastest growing medical imaging technology enables *SEEING THROUGH THE BODY BY LISTENING TO THE SOUND OF LIGHT*. TomoWave is focused on its first clinical product, the 3D Laser Optoacoustic Ultrasonic Imaging System Assembly for automated screening, diagnostic imaging and monitoring therapeutic interventions of breast cancer with significantly improved sensitivity and specificity, especially in younger women. This first product is especially valuable in the Asian market where women have dense breast and x-ray based mammography has significant limitations. In the pipeline of future technologies is also a medical laser ultrasound system and a universal laser optoacoustic ultrasonic imaging system capable of providing image guided biopsy and surgery and monitoring thermal therapy guided by optoacoustic temperature maps of the tissue volume being treated. The global market of TomoWave systems exceeds$5 Billion with China market rapidly growing to become the largest market approaching $2 Billion.

Phase of development:

Clinical validation / commercial system

Regulatory status (FDA and/or CE Mark):

Not submitted yet

Plan to submit NMPA, CE Medical and FDA in 2021

Brainstorm Medical

https://brainstorm-med.com/

Presentation Time at Breakout B: 14:41 – 14:50

Executive summary of your company:

Brainstorm Medical is a technology startup based in San Diego, California. We're developing an Artificial Intelligence software platform, called Brainstorm AI, to help emergency room physicians diagnosing patients with cardiovascular conditions. The value proposition is better patient care, improved physician experience, reduced hospital costs and risks of complications and litigations.

We use expert-curated high-quality private research databases to train our AI models, to achieve high accuracy, and avoid "garbage in, garbage out". We have access to such databases through personal relationships of our founder Dr. Alan Maisel, MD – a world renowned cardiologist who discovered the BNP biomarker for rapid diagnosis of heart failure.

We're partnering up with in-vitro diagnostic companies – the makers of relevant biomarkers. Brainstorm AI works in tandem with these biomarkers.

All three our founders are successful serial entrepreneurs.

Primary indication(s):

1. Myocardial Infarction (MI, Acute AMI or AMI or heart attack) – discerning between types 2 and 1.
2. Syncope (passing out / losing consciousness)
3. Pulmonary embolism
4. Shortness of breath
5. Atrial Fibrillation
6. Cardio-oncology
7. Heart failure (both acute and chronic)
8. Amyloidosis

Product/technology description:

Brainstorm AI is a software platform that hosts our proprietary AI models for clinical decision support. It uses APIs to seamlessly interface with EMR / EHR and the hospital's middleware software. Brainstorm AI works in real time by automatically identifying patients with cardiovascular conditions using our proprietary algorithms and presenting its diagnostic assessment and risk stratification in the existing graphic user interface window of the hospital's EMR software. Our type 1 vs. 2 MI product achieved 94.5% separation accuracy, that is significantly better than average emergency room physician.

Phase of development:

Prototype.

Regulatory status (FDA and/or CE Mark):

Not started. We have a sufficient amount of retrospective patient data to cover FDA testing requirements, in addition to our internal validation.

Fibralign Corp.

www.fibralignbio.com

Presentation Time at Breakout B: 14:51 – 15:00

Executive summary of your company:

Fibralign is a Stanford-spinout company that produces novel therapeutic medical devices to address major unmet medical needs. Its first product BioBridge is being targeted to address secondary lymphedema, a global chronic disease that affects over 15 million people and currently has no cure.

Fibralign is already commercially selling BioBridge in the US and has demonstrated clinical benefit in treating patients with this disease. The company is conducting a multi-site clinical study for breast cancer-related lymphedema ($3M funding from the National Cancer Institute), a preventative study in Europe and preparing for a clinical study in Japan (both partner funded).

The Company has established GMP production (ISO 13485 certified), a strong IP position (28 patents issued) and a compelling product pipeline.

Primary indication(s):

Secondary Lymphedema

Pipeline: peripheral artery disease (PAD), peripheral nerve repair, muscle regeneration

Product/technology description:

Fibralign's first product is the BioBridge® Collagen Matrix, a nanostructured scaffold that promote and direct the repair of lymphatic vessels (lymphangiogenesis) when implanted subcutaneous in the treatment area.

BioBridge has also been shown in preclinical studies to promote the repair of blood vessels (angiogenesis) and peripheral nerves and provide a novel delivery device for cells and gene therapy.

BioBridge utilizes Fibralign's Nanoweave® advanced materials technology platform that enable precise printing of 3D scaffolding which precisely mimics human tissue structure.

Phase of development:

Commercial stage, Clinical study phase

Regulatory status (FDA and/or CE Mark):

Initial FDA 510(k) clearance for first product. CE mark review in process. Preparing for Japan regulatory submission.

Yolia Health

www.yolia.com

Presentation Time at Breakout B: 15:01 – 15:10

Executive summary of your company:

Yolia Health has developed the 1st non-invasive and repeatable platform of treatments for vision problems such as myopia, presbyopia, hyperopia and post-surgical (LASIK and cataract) patients.

Yolia's True Vision Treatment (TVT) requires patients to use patented customized contact lenses and ophthalmic eye drops for only seven days. TVT results last for 12 months on average and can be repeated as needed. TVT is approved in Mexico and has recently been designated to CDRH (device) by the FDA. Estimated time for US approval by 2022.

Yolia Health is a Delaware Corporation founded in 2006 with more than 54 international patents and many more pending. Yolia is seeking to expand to Asia and is in search for institutional investors and local partnerships.

Primary indication(s):

Myopia, presbyopia, hyperopia, digital fatigue, post Lasik, post cataract.

Product/technology description:

Yolia's True Vision Treatment (TVT) mechanism of action works as follows: TVT's eye drops (hyaluronidase and collagenase) allow the cornea to be malleable while the unique designs of TVT's contact lenses reshape the curvature of the corneas. TVT can be used from three to seven days for an efficacy of 6 months, 12 months or longer. TVT is safe, reversible and repeatable.

Phase of development:

Commercial (soft launch)

Regulatory status (FDA and/or CE Mark):

Approved in Mexico as a medical device class II.

Designated to CDRH (device) by the US FDA. Estimated time for approval by 2022.

Pacific Diabetes Technologies, Inc.

www.pacificdt.com

Presentation Time at Breakout B: 15:11 – 15:20

Executive summary of your company:

Pacific Diabetes Technologies (PDT) is a privately-held clinical stage medical technology company developing devices that make insulin therapy more user-friendly. PDT has developed a hollow glucose sensor that allows insulin infusion and glucose monitoring from a single site, using only a single needle per week. This reduces the pain, hassle, and cost of managing insulin-treated diabetes, and improves the user experience for Automated Insulin Delivery systems. Tapping the $3B continuous glucose monitoring (CGM) market, our products include a CGM Infusion Set for insulin pumps, a needle-free CGM Port for insulin pens, and a CGM Infusion Cannula for use in tubeless patch pumps worn directly on the body.

Primary indication(s):

Insulin-treated diabetes

Product/technology description:

Our hollow glucose sensor uses a patent-pending redox mediator to avoid interference from insulin. Products include a CGM Infusion Set for insulin pumps and a CGM Infusion Cannula for use in tubeless patch pumps worn directly on the body. These allow Automated Insulin Delivery without the need for a separate glucose sensor system. Our CGM Port offers users 5-7 days of needle-free insulin infusion and glucose tracking, increasing compliance for reluctant patients, improving safety for professional caregivers, and reducing biohazard waste production and disposal costs.

Phase of development:

Clinical studies

Regulatory status (FDA and/or CE Mark):

US and Australian investigational device exemptions

ThermopeutiX, Inc.

www.thermopeutix.com

Presentation Time at Breakout B: 15:21 – 15:30

Executive summary of your company:

THERMOPEUTIX, INC. is a San Diego-based privately held company that offers imaginative, innovative and economical solutions to unmet medical needs. The medical specialties that are currently targeted include interventional cardiology and radiology, neuroradiology, neurosurgery, neurology and oncology. The Company's current product line — a proprietary family of patented and patent-pending CoolTools™— addresses the next frontiers in interventional medicine, advancing the treatment of vascular-related disorders and using the body's vascular system to provide therapy. In particular, the Company's patented TwinFlo™ Catheter technology is the only device that can safely and effectively protect the ischemic brain by providing rapid, selective, deep cerebral hypothermia, and has the potential to revolutionize the treatment of acute stroke.

Primary indication(s):

TwinFlo™ Catheter — Acute stroke, cardiac arrest, head trauma

Other products — Family of catheters for targeted vascular drug delivery

Product/technology description:

The patented TwinFlo@ catheter will transform the treatment of acute stroke by providing rapid, selective, deep cooling of the brain (cerebral hypothermia). Numerous studies have proven the potential for hypothermia to protect the brain where lack of oxygen threatens to destroy brain tissue. The unique design of TwinFlo™ results in more rapid and deeper localized cooling of the brain, while maintaining the remainder of the body at normal temperature ("selective hypothermia"). This differs from other hypothermia treatments that are unable to bring the brain to a sufficiently low temperature without significant total-body cooling and detrimental systemic effects. The design also permits selective drug and/or device delivery concurrent with the hypothermia treatment. Use of the catheter will be familiar to the large number of interventional physicians on staff at most hospitals.

Phase of development:

Beginning clinical studies

Regulatory status (FDA and/or CE Mark):

FDA 510(k) cleared; registered in China and Taiwan.

PhysioCue

www.physiocue.com

Presentation Time at Breakout B: 15:51 – 16:00

Executive summary of your company:

PhysioCue(www.physiocue.com) is a four-year-old consumer digital health and therapy device development company, located in the heart of Silicon Valley, that developed a non-invasive hypertension therapy device and a migraine and headache therapy device.

Our next generation hypertension therapy device that combines the biosensor technology for measuring blood pressure from the fingers, record and transmit the data via the PhysioCue app. and a bio-sensor BP monitor paired with an app. In just 30 seconds - no blood pressure cuffs!

Primary indication(s):

Med Technology, Medical device

Product/technology description:

Non-invasive hypertension therapy device and a migraine and headache therapy device. PhysioCue has developed thermal neurostimulation technology. The device generates a certain range of cold temperature with vibration in the mix to stimulate the baroreceptor of the carotid artery. Baroreceptors are the part of the principle parasympathetic system, regulating the blood pressure. PhysioCue technology enables to stimulate and condition the baroreceptor, and eventually balance autonomic system to gain the blood pressure control of the body.

Phase of development:

Beta customers

Regulatory status (FDA and/or CE Mark):

FDA resisted class I devices, applied class II 510(K) devices

PhotoniCare

www.photoni.care

Presentation Time at Breakout B: 16:01 – 16:10

Executive summary of your company:

PhotoniCare is building a low-cost diagnostic platform that uses light to see through tissue. The first product on this platform will fundamentally change the way physicians manage middle ear infections, the leading cause of hearing loss, antibiotic use, and surgeries in children, where the current gold standard is incorrect 50% of the time. With the TOMi Scope, physicians can now see through the eardrum to directly visualize the middle ear and determine whether antibiotic use or surgical intervention may be necessary. Diagnostic accuracy in a recent clinical study using the technology showed an accuracy of 90%+, suggesting significant improvement over the standard of care. The device is in use in multiple clinics in the U.S. and FDA clearance is expected soon. We are raising $10M to launch our first product and build out additional products on our platform in eye, dental, and consumer health markets.

Primary indication(s):

First product: Ear (middle ear diseases); subsequent indications in eye and dental.

Product/technology description:

PhotoniCare's TOMi Scope is a video otoscope that can see through the eardrum and directly visualize the middle ear contents. Specifically, it uses near-infrared light to visualize and determine the density of fluid in the middle ear. This enables the device to better diagnose middle ear infections and other middle ear diseases. The device has shown a 90% accuracy for determining fluid behind an intact eardrum, far better than the 50% accuracy of a traditional otoscope. The device uses a mechanism called low-coherence interferometry, which is basically the light-based analog to ultrasound imaging. It has been developed specifically for the demanding front-line care environment, where we expect it to be used in pediatric, urgent care, family practice, ENT, and retail clinics, where workflow is paramount and usability makes or breaks a new entrant.

Phase of development:

On the market

Regulatory status (FDA and/or CE Mark):

FDA approved. CE Mark and PMDA in process.

Replication Medical, Inc.

www.replicationmedical.com

Presentation Time at Breakout B: 16:11 – 16:20

Executive summary of your company:

Replication Medical Inc. Company" is an exciting medical device company developing next generation spinal implants for chronic low back pain due to spinal stenosis and degenerative disc disease. The company has a distinct competitive advantage offering novel shape-memory hydrogel implants for motion preserving spine surgery in an interventional or minimally invasive outpatient setting. ▪ Company seeks to establish its two breakthrough platform solutions as an efficient, safe, cost effective, and patient-friendly alternative to opioids and existing spinal procedures including fusion. ▪ Replication Medical is a commercial stage company with demonstrated marketability of their innovative product platforms, which are well differentiated from competition within the spinal surgery space. ▪ The company is seeking a strategic partner to expand their innovative product platforms in the US or internationally and will consider all value creating alternatives, including distribution and sub-licensing agreements to merger or acquisition.

Primary indication(s):

Pain management, spine surgery, axial back/leg pain and spinal stenosis, degenerative disc disease

Product/technology description:

The company's lead product is a proprietary hydrogel technology GelStix injected percutaneously via a 18-gauge needle into the nucleus of an intervertebral disc to eliminate pain. It's designed to fill a gap in treatment options between conservative care (physical therapy, etc.) and surgical interventions (discectomy, total disc replacement and fusion).Nearly 30% of people experience low back pain each year generating an estimated $150+ billion in direct medical and indirect medical expenses annually, making low back pain one of the most expensive health care concerns today. Chronic low back pain is the number one reason U.S. doctors prescribe opioids and it is estimated that more than 1% of Americans regularly take prescription opioids for back pain . For patients who have failed conservative care, GelStix provides a non-surgical, non-addictive treatment for chronic low back pain. The Company has also developed GelFix, a ground-breaking in-vivo expanding interspinous spacer for treating back and leg pain.

Phase of development:

Early commercial stage

Regulatory status (FDA and/or CE Mark):

CE Mark, GMP, ISO13485:2016

Cosm Medical

www.cosm.care

Presentation Time at Breakout B: 16:21 – 16:30

Executive summary of your company:

Pelvic Floor disorders are common, growing and underserved. They include prolapse and incontinence which affects half of all women by 80 years of age. Surgery in this field has major issues that led the FDA to ban surgical mesh in Apr 2019; current gynecological prosthetics, known as pessaries, come in 100+ shapes and sizes fit by trial and error.
Cosm Medical is combining a proprietary ultrasound-based measurement system with data science and 3D printing to create a platform for Gynethotics, or the world's first custom gynecological prosthetic so more woman can live and age with dignity and grace.
Join us in our mission for Personal Pelvic Health.

Primary indication(s):

Pelvic Organ Prolapse, Urinary Incontinence, Fecal Incontinence

Product/technology description:

We are developing a platform to create Gynethotics.

Our first technology is a proprietary manometry + ultrasound system to measure the physiological and biomechanical characteristics of the pelvic floor.

The measurements get sent to the Cloud where our software analyzes the medical images and data to generate a patient specific CAD model which is then queued for manufacturing.

Manufacturing is done through a combination of standard and additive manufacturing (ie. 3D printing) techniques to create a biocompatible device to each women's unique body and needs.

Phase of development:

In Clinical Pilot Testing

Regulatory status (FDA and/or CE Mark):

Expected by Q4 2021

Nanochon

http://www.nanochon.com

Presentation Time at Breakout B: 16:31 – 16:40

Executive summary of your company:

Nanochon is developing a 3D printed soft implant to resurface damaged areas of cartilage in the knee. Focused on younger and more active patients, the device works by replacing lost cartilage and growing new healthy tissue over time, to greatly accelerate recovery and delay or negate the need for a knee replacement. The device is also a low cost / high volume manufactured implant, which may reduce cost compared to the standard of care by up to 20X.

Primary indication(s):

Cartilage resurfacing, plastic surgery and trauma

Product/technology description:

The Nanochon device is a combination of novel 3D printed structures and a unique nano-material polymer. These combine to make a device which 1) has cartilage like properties 2) is flexible and durable to facilitate arthroscopy and 3) recruit stem cells in the body and then guide cartilage growth.

Phase of development:

Pre-clinical proof of concept, animal studies

Regulatory status (FDA and/or CE Mark):

FDA pre-submission meeting

Eyedetec Medical, Inc.

www.eyedetec.com

Presentation Time at Breakout B: 16:41 – 16:50

Executive summary of your company:

Dry Eye Disease (DED) significantly impacts quality of life, and the incidence is growing 7% annually (30M patients in US, 200M in China, 350M worldwide). Eyedetec Medical is developing a new treatment that is easier to use, much more comfortable for the patient, and significantly less expensive than alternatives.

We have developed the Eye Lipid Mobilizer™ (ELM). Proof-of-concept clinical data (n=40) demonstrates that the device works as anticipated, improves signs and symptoms, and is strongly preferred by patients. We have broad patent protection with confirmed freedom to operate. The company's Advisors are among the top DED experts in the world.

Next steps include a multicenter clinical study and regulatory filing. The low risk regulatory pathway is a Class II 510(k) and Class IIa CE mark. A commercial ready product is anticipated in 12-18 months following funding of a planned $5M Series A equity financing.

Primary indication(s):

Treatment of Dry Eye Disease and Meibomian Gland Dysfunction

Product/technology description:

The Eye Lipid Mobilizer™ (ELM) deploys a novel, patent protected technology (Resonant Frequency Stimulation) to mobilize lipids (oils called meibum) from within the Meibomian Glands of all 4 eyelids simultaneously. These lipids provide a protective cover over the ocular surface, by naturally preventing tear film evaporation. The advanced technology is protected by 5 patents, with confirmed Freedom to Operate. The ELM is intended for use by a physician or technician in their clinic/office. The procedure is pleasurable for the patient, and easily delivered during a 15 minute, fully automated treatment session.

The ELM device is comprised of 3 components:

Controller Console

- Power
- User control
- Built in logic
- Connector to Headset
- Interface storage & warmer

Headset

- Molds to Interface
- Delivers Heat
- Delivers RFS

Interface (single use, high margin disposable)

- Molds to eyelids' surfaces
- Transfers energy to eyelids
- Moistens eyelash exudate

Phase of development:

Product developed, planning multicenter clinical study and regulatory filings.

Regulatory status (FDA and/or CE Mark):

Low risk, Class II 510(k) and IIa CE Mark.

Vave Health

www.vavehealth.com

Presentation Time at Breakout B: 15:31 – 15:40

Executive summary of your company:

Vave Health is a medical device company creating ultrasound products and services. It was founded in Dec 2014 and is currently based out of Santa Clara, CA with 29 full time employees. Its product consists of a personal, portable ultrasound probe and an AI-powered software platform designed to deliver value-added services such as guided-image capture, assisted interpretation, and ultrasound education services. Vave's target market includes physicians, hospitals and medical education, with an initial focus on specific physicians, i.e. hospitalists, intensivists, and anesthesiologists, as well as medical education in the US market in 2020. Vave will be using a subscription-based business model, with high-level projections of 6-8K subscribers in 2020 and growing to 20-25K and 60-70K in 2021 and 2022, respectively – amounting to ~$7.2M ARR in 2020, ~$28.1M ARR in 2021, and ~$71.7M ARR in 2022.

Primary indication(s):

Product/technology description:

Vave ultrasound probe is a personal, portable, wireless device that captures ultrasound images in conjunction with the Vave Health app when connected to a phone or tablet. It delivers superb image quality in a pocket-size, wireless device, has a price point that enables mass, personal adoption, and is compatible with both iOS and Android devices. Our app delivers additional ultrasound services such as guided-image capture and assisted interpretation through our AI-powered platform.

Phase of development:

FDA cleared, pre-revenue and pre-commercial

Regulatory status (FDA and/or CE Mark):

FDA cleared

QT Vascular/TriReme Medical

https://qtvascular.com/us/

Presentation Time at Breakout B: 17:31 – 17:40

Executive summary of your company:

TriReme Medical is a California based company, a subsidiary of QT Vascular, listed on the SGX. TriReme has developed & commercialized the Chocolate™ peripheral and Chocolate PTCA™ balloon catheters uniquely designed with a nitinol constraining structure for atraumatic balloon dilatation of arterial lesions. Both technologies were acquired by Medtronic and Teleflex, respectively, after long-term successful OEM supply relationships.

Primary indication(s):

Peripheral vascular arterial disease/lesions/occlusions.

Product/technology description:

The Chocolate Touch™ technology is similar to that which Medtronic acquired but with the addition of a paclitaxel, anti-restenotic drug-coating. Previous studies have shown superior outcomes to commercialized products in the same space.

Phase of development:

Fully developed and commercialized in some countries via a limited market release.

Regulatory status (FDA and/or CE Mark):

CE mark approved. Currently 95% enrolled in an FDA IDE study, targeted to complete enrollment in Q1 2020, followed by a 12-month follow-up, the FDA submission.

iHEAR Medical, Inc.

www.ihearmedical.com

Presentation Time at Breakout B: 17:41 – 17:50

Executive summary of your company:

iHEAR Medical, Inc. is a venture-backed firm dedicated to addressing the global need for affordable and accessible hearing solutions. iHEAR is pioneering direct-to-consumer and OTC hearing products with over 50 patents issued and pending. iHEAR's cloud-based platform delivers effective hearing solutions at a fraction of the cost of conventional hearing aids which cost over $5,000 for a pair, bringing the price of a customized hearing aid to under $500 and in line with prescription eyeglasses. iHEAR's FDA approved products are currently sold in the USA online and at major pharmacies including CVS and Walgreens.

Primary indication(s):

Hearing loss in the ranges of mild, moderate up to severe.

Product/technology description:

-iHEARtest: the only FDA-approved home hearing test kit on the market

- Medical-grade FDA-registered hearing aids
- Advanced hearing amplifiers sold OTC
- Remote programming and customer support
- 50 patents issued and pending

Phase of development:

In commercialization, On the market

Regulatory status (FDA and/or CE Mark):

US FDA approval and registration for all products.

Pending CFDA approval in China.

COMPANY PRESENTATION TRACK

ROOM SEQUOIA

TIME	SESSION
10:00-10:05	**Opening** Ginger Ding, Director of Investment Analyst, MyBioGate
10:05-12:30	**Company Presentation**
12:30-13:30	**Lunch Break**
13:30-14:30	**Company Presentation**
14:30-15:15	**Gain Insights in Dealmaking by Hearing Real World Case Studies** Zhenhua Wu - CEO, Exegenesis Bio David Poon - Vice President of Business Development, Zymeworks Shawn Zhang - Vice President, Ambrx Anu Balendran - Vice President Business Development, Alligator Bioscience Darrin Crisitello - Chief Commercial Officer, Mission Bio James Lee - Sr. Business Development Manager, Atomwise
15:15-17:00	**Company Presentation**

SPONSORED BY GLORIA BIOSCIENCES

gloria 誉衡生物
BIOSCIENCES

PRESENTING COMPANY SUMMARY

Targovax (OSE:TRVX)

Targovax is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax' s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Flow Pharma

Flow Pharma is an immuno-oncology company based in the San Francisco Bay Area, with subsidiary companies in China and Australia. The company developed a high-yield and low-cost neoantigen delivery system that can effectively treat a wide variety of cancers and viral diseases. Our pipeline include an Ebola vaccine, a cervical cancer/cervical lesion and head and neck cancer vaccine and a personalized breast cancer vaccine. The company is poised to initiate Phase I and Phase IIa studies in 2020.

Cerenetex

Strokes affect 15 million people worldwide, causing hemorrhagic complications, permanent disability, dependency, and death. At Cerenetex, we're leading the science of objectively diagnosing Large Vessel Occlusion (LVO) ischemic strokes to minimize the delay in care and injury to the brain. Cerenetex is the leading company focused specifically on the science, development, and commercialization of acoustic-based technologies for the non-invasive detection of neuropathologies. We are passionate about providing objective diagnostics to enhance therapy and time to treatment for patients suffering from ischemic strokes by providing innovative, clinically proven and economically effective diagnostic solutions for physicians and health care providers.

Gloria Biosciences

Gloria is committed to the development of cutting-edge biological medicinal products, providing cancer patients worldwide with innovative solutions, and reduction of the disease burden for societies. Supported by a strong international standard experienced commercial team, an FDA GMP certified CMC production and supply facility, and international business and collaboration partners working together, Gloria strictly follows the ICH-GCP Guidelines, executes clinical trials scientifically and efficiently, and is dedicated to bringing more high-quality, innovative, affordable drugs to health professionals and patients across the world.

Dyadic International

Dyadic is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system. C1 is a fungal based gene expression platform with unique features in its growth and production capabilities and has anticipated competitive advantages compared to other pharmaceutical expression systems, such as CHO, E.coli, yeast, insect cells and other organisms currently in use. Dyadic is based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and CRO' s in Finland and Spain. Dyadic is currently looking for business partners and research collaborators in China to bring its disruptive C1 gene expression platform to the Chinese healthcare market.

Maintect GmbH

Maintect was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists. Maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don' t benefit from anti-VEGF treatment. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment.

Zhimeng Biopharma

Founded in 2017 and located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, Zhimeng Biopharma is developing innovative medicines for the treatments of 2 important diseases in China: chronic hepatitis B and severe neurological disorders. Leveraging the company founders' rich expertise, Zhimeng has invented 3 drug assets for each of these implications. Zhimeng is quickly bringing these products to clinical development. A phase I clinical trial on its novel HBV capsid inhibitor will start in January 2020. Zhimeng welcomes investment partners and strategic collaborators to work together to quickly bring innovative drug products to clinical development and to patients.

Virometix

Virometix is a Swiss biotechnology company developing next-generation synthetic vaccines to prevent infectious diseases and treat chronic diseases. The company has two proprietary technologies: Synthetic Antigen Mimetics (SAMs) and a Synthetic Virus-Like Particle (SVLP) platform to deliver and present SAMS to the immune system. Manufactured synthetically, these vaccines are inexpensive, easy-to-produce, modular, and customizable. They do not require the addition of adjuvants. Based on strong preclinical data and a validated target, the lead asset, V-306, is about to enter Phase 1 in RSV. Success in the project will provide a proof-of-concept to leverage the promising pipeline in infectious diseases and oncology. Virometix is seeking a licensing partner for China and/or a Chinese strategic investor for a co-development agreement.

Denovo Biopharma

Denovo is a clinical stage biopharmaceutical company that applies novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. The company seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo is enrolling patients in the U.S. and China with diffuse large B-cell lymphoma (DLBCL) in a Phase 3 clinical trial and will start a phase 2B study in Glioblastoma (GBM) for its lead product candidate, DB102, which was in-licensed from Eli Lilly. The company has four additional late stage programs targeting major unmet needs: DB103 for schizophrenia, DB104 for depression, DB105 for Alzheimer' s Disease, and DB106 for acute myeloid leukemia (AML).

OncoGenesis

Every 2 minutes, a woman dies from Cervical Cancer. In 2018, there were 311,000 deaths and 570,000 new cases reported. 85% of these deaths occurred in developing regions with 1 in 3 occurring in China! The cause? Lack of ACCESS and resources to provide simple screening for a very treatable cancer ... if detected early! OncoGenesis is offering "game-changing" technology to address women who needlessly die due to the lack of a simple, reliable and cost-effective means to screen for cervical disease. OncoGenesis brings to the marketplace iPap™, a patented sample self-collection device coupled with CerMark™ Point-of-Care and LAB systems that detects persistent high-risk HPV infections (the cause of cervical disease) as well as evidence and prognostic risk of precancerous lesions. Initially targeting the unmet needs of women in the developing world markets, OncoGenesis CerMark offers convenience to women in the developed world markets as well. Similar in approach to at-home colon cancer screening, (e.g. Cologuard®), OncoGenesis' iPap & CerMark systems support self-sampling and near instant results provided by pharmacy, clinic or MD office.

Huirui Biopharma

Huirui develops First-in Class therapeutics focusing on saccharide-based targets. The company owns a rich product pipeline including small molecule and monoclonal antibodies for the treatment of influenza infection, autoimmune diseases and tumors. The anti-influenza product demonstrated a significant improvement of healthy score and decrease in death rate compared to the commercially available product (Tamiflu) in the animal models with multiple flu viral strains. Its Phase I clinical study is expected to be initiated within one year. Huirui' s technologies and product pipeline are protected by a number of worldwide invention patents. The company's management team consists of experienced overseas experts with complementary professional strengths.

Celsion

Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Wyze Biotech

Wyze is a clinic stage company engaged in the development and commercialization of universal T cell technologies for cancer immunotherapy. The company was established in Hangzhou, China in February 2012 and has four first-in-class cell products in the pipeline. The first product RC1012 (allogenic DNT cells) treats relapse and refractory AML that is well tolerated across two dose levels with minimal side effects, and diminishes disease burden when administered as a monotherapy. The results from the allogeneic DNT cells immunotherapy so far have practice-changing implications for the field of oncology by improving survival rates and drastically expanding patient access to treatment.

Strateos, Inc.

Strateos has developed the on demand Strateos Cloud Lab to accelerate life sciences with full automation of laboratory workflows --speeding discovery of new pharmaceuticals and new biology tools such as synthetic biology. The robotic platforms we use to create a rapid design-make-test-analyze cycle are accessible from around the globe, freeing researchers to start their work quickly with an easy web access. By using robotics, we produce high quality data with high reproducibility as compared to today' s often slow, error-prone methods. These data can in turn be used to build artificial intelligence models to further speed discovery.

Gero

Gero is a biotech company using a proprietary next-generation AI platform for big biomedical data analysis to discover therapeutics targeting aging. Primary indication: Accelerated aging after chemotherapy/cancer supportive care. Follow-up indications: metabolic syndrome (including NAEFL/NASH); regeneration; rejuvenation; neurogenesis/neuroplasticity; other "hallmarks of aging" . Facts about Gero: Top-notch AI investors with exits to Google and Facebook; outstanding lifespan extension and rejuvenation in aged mice (collaboration with B. Kennedy from NUS (ex CEO of the Buck Institute of Aging); collaborations with researchers from Harvard, MIT, Roswell Park Cancer Center. Gero seeks $10M round. Exit in up to 4 years after efficacy demonstration in humans.

Bayer (China)

Bayer (China) is a leading multinational pharma company in China with leadership in China' s key therapeutic areas such as Diabetes, Cardiovascular, Anti-infectious, Oncology, Women' s Health, etc. With broad coverage across geographies and strong commercial footprint across hospital tiers, Bayer has strong track record in achievement of registration, market access and commercial performance safeguarded by legal and patent protection capability. Dedicated R&D center and state-of-the-art production facilities clearly demonstrate Bayer' s long-term commitment to serving unmet patient needs in China. Bayer welcomes open innovation and partnership, jointly contributing to the healthcare development in China.

VivaLNK

VivaLNK provides an integrated medical IoT platform composed of the world' s most comprehensive vital sign wearable monitor, edge computing, and advanced cloud health data analytics. The company provides its Platform as a Service to over 80 commercial customers, in both US and China, with $1M revenue in 2019. Examples include Mercy Hospital, Shanghai Public Health Clinical Center, UCSF, and Stanford.Its Band-Aid sized medical-grade monitor is the only device in the world that can perform Blood Pressure, ECG, Respiration, Body Temperature, and Stethoscope functions for wireless patient monitoring. Additional advanced predictive algorithms are under development, in collaboration with world' s top research institutions, for early disease detection and diagnosis. VivaLNK has a very strong med tech team, including PhD' s and MD' s with proven track record in medical device and IoT systems.

Canary Speech

At its core, Canary Speech is a speech and language company, specializing in identifying disease and human condition through speech. Canary Speech technology is patent protected, with three issued US patents and three additional patents pending in the US and internationally. On the cutting edge of a major medical breakthrough to reduce costs, expand telehealth and remote medical services, provide screening for a range of diseases and thus enabling organizations to improve quality of life.

We have achieved breakthrough IRB studies and FDA clinical trials in Alzheimer' s disease, Parkinson' s and depression related to suicide prevention and the treatment of PTSD. Canary Speech is also engaged in the study of cognitive function, MCI (Mild Cognitive Impairment), stress, anxiety, and schizophrenia.

TECLens

Based in Stamford, CT, TECLens is a clinical-stage medical device company developing an innovative, non-invasive cornea cross-linking procedure to treat keratoconus, low order myopia and eventually presbyopia. TECLens' proprietary 'on-eye' CXL technology consists of a single-use disposable contact lens (CXLens®) and a small control system. The system can treat both eyes simultaneously for keratoconus, and provides integrated real-time ultrasound feedback and patterned ultraviolet light delivery for refractive indications. TECLens believes on-eye cross-linking will become a safe, simple, and permanent alternative to LASIK, contact lenses, and eyeglasses for millions of people with vision errors.

Avotres

Avotres is raising up to $30-50 million to focus on autoimmune diseases (AID) and cancers by targeting a novel CD8+ regulatory T cell (Treg) pathway, a core mechanism regulating peripheral immune self-tolerance. AVT001: autologous dendritic cell therapy to address the root cause, and as a first potential cure for multiple AID. Currently in a phase I/II trial for Type 1 Diabetes. Proof of concept trials planned for additional AID with high unmet needs. AVT002: preclinical stage, antibody-based therapy for a new immuno-oncology target, to reduce cancer recurrence and as a synergistic combination therapy. IND ready in 2-3 years.

Erythra

Accurate diagnosis, Effective treatment, and Affordable healthcare can be achieved by well understanding of the mechanism of disease pathogenesis and identifying their critical components. Erythra owns the patents of the methods of exploiting the role of erythrocytes in immune tolerance. In effect, Erythra developed a comprehensive test for TB diagnosis and monitoring and a screening test for the diagnosis of colorectal cancer. Similar tests for all infectious diseases and other cancers can be developed the same way. Further, this role of erythrocytes will enable the accurate diagnosis and simple effective treatment of autoimmune diseases, transplanted organ rejection, and other diseases."

Curevo Vaccine

Curevo is a US-based clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently.

Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, is in Phase I (90 subject trial). Interim results are showing a promising safety profile and the desired immune responses. We are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.

On the strength of our clinical data and pre-clinical pipeline, we are looking for partners and investors to support the next stage of clinical development.

METiS Pharmaceuticals

METiS is a venture-backed, preclinical biotech company. Our team of MIT researchers and serial entrepreneurs built the world's first AI-driven formulation platform to enable targeted, smart 505(b)(2) and novel drug candidates. Through the integration of machine learning, quantum simulation, and high-throughput experimentation, we enable formulation scientists to rapidly, comprehensively and intelligently develop clinically differentiable products. These disruptive ways of working fundamentally transform drug discovery, drug development and product lifecycle management, and ultimately bring more quality drug products to patients.

Kintor Pharmaceutical Limited

Kintor is a clinical-stage novel drugs developer in China focusing on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other AR-related (antrogen receptor) diseases. It had developed five clinical-stage drug candidates. The lead product, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in US for mCRPC as well as clinical trials for breast cancer. Kintor’ s mission is to become a global leader in the research, development and commercialisation of innovative therapies, focusing on indications with substantial unmet medical needs, in particular in the AR-related field.

亦度正康
YEEDOZENCOM

About YEEDOZENCOM

Founded in 2010, with more than 300 employees, Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd. provides professional R&D outsourcing services from regulatory affairs, compliance audit, to clinical trials for registration and post-marketing studies for pharmaceuticals.

Corporate Culture

- Core Value: Scientific, Integrity, Collegiality & Sharing
- Corporate Vision: Become a leading provider of full lifecycle technical services for pharmaceutical products
- Our Mission: Provide value-added and lifecycle technical services for pharmaceutical companies

Main Services

1. RA Service & Strategy: Imported drug registration, domestic drug registration, registration strategy, consulting service of Routine Regulatory affairs and regulatory technology issues, etc.
2. Clinical Trial Operation: Phase I-IV Clinical Trials, BE, Real World Study, etc.
3. Medical Affairs: Clinical trial protocol design & writing, clinical summary report draft & review, pharmacovigilance, etc.
4. DMPK: Pre-clinical, clinical, radioactive and non-radioactive DMPK research
5. SMO Service: Site management services for clinical trials
6. Biological Analysis: Providing clinical biological sample analysis service which complies with NMPA and FDA guidelines
7. Data Management & Statistic Analysis: Data management, biological statistics, Meta analysis
8. Inspection & Audit: Compliance on-site audit to investigative sites, manufacturing sites, etc.

Management Team

Dr. Zhi'ang Wu
Chairman
Professor of Shenyang Pharmaceutical University;
Former Assistant Director of CDE
Former Deputy Director of CDR

Mr. Lingyun Dong
General Manager
Former Director of CDE Information Dept.
Participated the draft and revision of current drug registration
regulations, and the design of CDE drug review systems.

Dr. Ruoming Zhang
Executive Deputy General Manager
Doctor of Science, China Pharmaceutical University, Former
Reviewer and Project Leader of
Oncology and Digestology fields in CDE

Dr. Zhen Chen
Chief Scientist, Deputy General Manager
Doctor of Institute of Materia Medica, Chinese Academy of Medical Sciences,
Professor of Zhengzhou University
Former Head of Chemical Drug Dept. I (Chemical Drug & New Drug Evaluation) in CDE

Partners

Wyeth · SANOFI · FRESENIUS KABI · Dr.Reddy's · MERCK SERONO · Nobel pharma
SINQI · 药友制药 YAOPHARMA · 天津金耀集团有限公司 TIANJIN KINGYORK GROUP CO., LTD. · 山东新华制药股份有限公司
绿竹生物 · ZEIN Pharmaceutical 植恩药业 · 鲁南制药 健康世界 KEEPING THE WORLD HEALTHY · TIPR

Contact Us

Beijing Yeedozencom Healthcare Science & Technology Co., Ltd.
Address: 9th Floor, No. 5, Bldg., GTCF Plaza, No. 9 Guang'an St., Fengtai District, Beijing, 100055, China
Website: www.yeedo.com.cn/en

Ms. Julia Huang
Deputy General Manager & Head of Business Department
Cell: 0086-13605160442
Email: huanghaiyan@yeedo.com.cn

Mr. Leon Li
Business Development Director
Cell: 0086-18500978653
Email: lihejun@yeedo.com.cn

YEEDOZENCOM, to help your product into China

gloria 誉衡生物 BIOSCIENCES

GLORIOUS FUTURE

Together with Gloria Biosciences to Success in China

Global Vision

Leading the Science

gloria

Affordable

Innovative

Oncology Focused

Reliable Quality

Start New Success in China

with Bayer

Our commitment started from 138 years ago.
Today, with ever changing environment and needs,
we are ready for a new era and shared future.

Zhimeng Biopharma (Shanghai)

www.corebiopharma.com
www.zhimengbiopharma.com

Founded in 2017 and located in the resource-rich Zhangjiang High-Tech Park of Shanghai with vibrant economy, Zhimeng Biopharma is developing innovative medicines for unmet medical needs in two important disease areas: chronic hepatitis B and severe neurological disorders. Leveraging the company founders' rich expertise in drug discovery and development, Zhimeng has invented 3 drug assets for each of these indications. Zhimeng is poised to quickly bring these products to clinical development. A phase I clinical trial on its novel HBV capsid inhibitor will start in January 2020. Zhimeng is currently seeking for financial investments and welcoming strategic collaboration to bring innovative, effective, safe and affordable drugs to improve the quality of lives of millions of patients.





Therapeutic Area	Indication	Product	Discovery	Lead Optimization	IND Enabling	Phase 1
Liver Diseases	HBV	Capsid inhibitor				
		RNA destabilizer				
		TLR8 agonist				
Neurological Diseases	Epilepsy	KCNQ2/3 opener				
	Pain/ Depression	KCNQ2/3 opener				
	Stroke	PSD95 antagonist				

Contact Information:

Huanming Chen, PhD
Chief Executive Officer
Mobile: +86 139 1875 6202
hchen@corebiopharma.com

Zhijun Zhang, PhD
Chief Scientific Officer
Mobile: +86 185 0009 8983
zzhang@corebiopharma.com

General Overview

Nanjing Jiangbei New Area, established on June 27, 2015 with the approval of the State Council, is the 13th State-level New Area in China and the only one of its kind in Jiangsu Province. Located on the north of the Yangtze River in Nanjing with a planned area of 788 square kilometers, it is by so far having the shortest distance to central downtown amongst all New Areas in China, and also a national comprehensive functional region undertaking the “Belt and Road” initiative and the national development strategy of the Yangtze River Economic Belt.

Industrial Layout

City of Chip

Nanjing Jiangbei New Area focuses on building a complete industrial chain of integrated circuit design, wafer manufacturing, packaging and testing, and supporting materials, and set up a number of high-level public technical service platforms and R&D institutions. By 2020, it expects to gather 300+ IC enterprises, 20+ IC design enterprises among the world’s top 50, and 1000+ IC talents, forming the industry cluster worth of billions, and growing itself a core town for integrated circuit in the Yangtze River Delta, a national leading industry agglomeration, and “a city of chip” with global influence.

City of Genes

Based on platforms of Nanjing Jiangbei Biotech and Pharmaceutical Valley and international Healthcare Area, Nanjing Jiangbei will build a national big data center for health to develop into a complete gene industry chain city of Gene sequencing, gene therapy, gene health and gene equipment, a gene cell city with global influence, a biomedical innovation resource collection platform, and a pilot area for building life and health innovation city.

New Financial Center

Centering on the new key industries, more efforts will be made in the introduction and cultivation of new financial industries, and gather new financial forms such as financial assets management, equity investment, and insurance innovation to strive to build a major new global financial center with strong capacity for capital absorption, integration of industry and finance, and innovation and transformation, and become a financial fulcrum with great influence and driving force in China.

Industrial platform

Nanjing Biotech and Pharmaceutcial Valley(NJBPV)

“Nanjing Biotech and Pharmaceutcial Valley(NJBPV)”

With a planned area of 14.92 square kilometers, it has gathered more than 600 Biomedical enterprises to focus on developing innovative new drugs and high-end medical devices represented by gene/molecular biotechnology. In addition, more emphasis will be placed on fostering innovation-driven modern medical science and technology services such as medical research and translational medicine, medical testing, Internet medicine, and health management. It is a professional industrial park which meets in whole life cycle of enterprise business development needs, and providing the rent subsidies for high-end innovation enterprise, market-based financing incentives, innovation incentives, equity reform and listing incentives,and other preferential policies.

（1）Nanjing BPV has Nanjing Jiangbei New Area Biopharmaceutical Public Service platform, National Resource for Mutant Mice, Preclinical Research Laboratory and other public technology service platforms, providing various instruments and equipment, information retrieval service, technology development and other services for drug research and development enterprises.It has established professional technology platforms, including New Drug R&D, detection and analysis, gene sequencing and mass spectrometry.

（2）The New Drug testing platform has built specialized laboratories covering the major fields of chemical synthesis analysis & molecular biology. Gene sequencing platform and big data center, as the basic conditions of the national health and medical big data center, also provides important hardware conditions and data support for the research and development of biomedicine and precision medicine technology.

（3）Nanjing Precision Medical Laboratory(PML) has purchased almost 100 units of comprehensive equipment such as Illumina series sequencers,ABI sanger sequencing machine and offered standardized laboratories of cell rooms, PCR labs and so on. It has established a technical platform with clinical molecular biology and cytogenetics as the core, covering clinical immunity, serology and other subjects.

“Nanjing International Healthcare Area”With a planned area of 5.6 square kilometers, it is based on the dual-core development model of technology innovation and international cooperation, is constructing an innovation cluster covering modern health and medical service industry, including medical care, education, research, rehabilitation and elderly care. The projects under construction including Gulou Hospital Jiangbei International Hospital, Cambridge University-Nanjing Science and Technology Innovation Center, Nightingale School of Nursing of King’s College London, etc.

JIANGSU INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

JITRI
JIANGSU INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Established in December 2013, Jiangsu Industrial Technology Research Institute (JITRI) is chartered with the crucial role of promoting and supporting industrial technology research, innovation and commercialization to promote the economic development of Jiangsu Province.

With good facilities and research teams for cooperation, excellent relationships with industry (thousands of partners), and strong financial and policy support, JITRI aims to be one of the leading industrial technology research centers in China and to provide a bridge between the Province and the international innovation community. JITRI focuses on supporting transformational research to close the gap between fundamental research, industrialization and commercialization. It focuses on research that serves industry needs arising from economic structure transformation and supports industrial innovation and market oriented product development.

In September 2016, JITRI Corporation was officially registered to support direct investment in R & D institutions and start-ups. So far, JITRI has 50 specialized research institutes spanning fields such as: Advanced Materials, Biomedical and Pharmaceutical, Intelligent Manufacturing & Equipment, Information Technology, and Environmental Protection. Overall, there are over 6,000 personnel under the JITRI umbrella, about 500,000 ㎡ of operating sites, 2.6 billion RMB (US$ 500 million) of equipment and total annual R&D expenditures of about 1.5 billion RMB (US$ 300 million). There have been nearly 1,000 technological outcomes transferred and transformed by the various specialized research institutes. About 260 start-ups have been established, 17 of them have gone public or are about to go public. So far, JITRI has also established 42 Enterprise Joint Innovation Centers with leading enterprises from related industries in Jiangsu Province.

JITRI has great flexibility to support international innovation, and is looking to partner with:

- Universities, research institute and professors:
  joint research projects, joint Ph.D. program, joint workshop, etc.
- Industries, start-ups and entrepreneurs:
  joint venture of R&D , research platform, direct investment, etc.

CUBIO INNOVATION CENTER

CUBIO is a healthcare incubator and innovative co-working space that not only provides healthcare innovators with office space but also with access to a wide range of diverse resources from human capital, business partners, to investors.

Our mission is to eliminate obstacles faced by innovative companies that are eager to enter China, and help Chinese companies expand and connect with local resources, and to make Houston the epicenter for US-China Cross-border collaboration.

CUBIO puts every effort out to help entrepreneurs and startups looking for an advantageous office location, positioning their businesses with cross-border collaborators and assist with legal, financial and consultant needs.



Amenities:

- » All-new office furniture
- » Super-fast internet
- » Daily cleaning
- » IT support
- » Onsite staff
- » 24/7 building access
- » Global Network
- » Office phone
- » Coffee & tea break
- » Business class printers
- » Microwave oven
- » Table top oven
- » Mail & package handling
- » Conference rooms
- » Dedicated & complimentary event space
- » Professional and social events
- » Unique common areas
- » Free visitor parking*
- » Ground parking $35/car/mo, garage parking $75/car/mo

RENT:

- Private office starting at $795/mo
- Dedicated Desk: $500/mo/desk
- CUBIO pass: $300/mo
- Virtual Office $175/mo

16,000sf. co-working space, free conference rooms, free 2,000sf. event vanue for all professional events. Just ask us!

Additional add-on services and incubation/investment opportunities for specific businesses are available, talk to us!

Fannin Professional Building, 7707 Fannin Street, Ste. 200, Houston, TX 77054

1-832-491-0069

info@cubioinnovation.com

https://cubioinnovation.com

PLATINUM SPONSOR

亦度正康 YEEDOZENCOM

gloria 誉衡生物 BIOSCIENCES

GOLD SPONSOR

JITRI JIANGSU INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

南京江北新区 NANJING JIANGBEI NEW AREA

BPV 南京生物医药谷 NANJING BIOTECH AND PHARMACEUTICAL VALLEY

BAYER

ZM 上海挚盟医药科技有限公司 ZHIMENG BIOPHARMA

MEDIA PARTNERS

CABS Chinese-American Bio/Pharmaceutical Society 北美华人生物医药协会

MSQ VENTURES

BIOHOUSTON BUILDING THE LIFE SCIENCE FUTURE

AAMI Advancing Safety in Health Technology

美中药协 SAPA

CHINA BRIEFS 中国快报

Biobanking.com Key to precision medicine

THE LIFE SCIENCE INVESTMENT DAYS

WORLD PHARMA TODAY

INSIGHT PHARMA REPORTS Expert Intelligence for Better Decisions

PM360 THE ESSENTIAL RESOURCE FOR PHARMA MARKETERS

GENE ONLINE

PHACILITATE LEADERS WORLD STEM CELL SUMMIT ADVANCED THERAPIES WEEK

BioKatalyst Inspire Biopharma Commercial Leadership

iMeta 艾美达

CHINAMED CAPITAL | 斐药圈

同写意 TONGXIEYI

NiiC

DRUG TIMES 药时代

医世象 MEDHEALIFE.COM

易企说17Talk

大医编 China Medical Editor

CHINA FOCUS®

CHINA FOCUS® @EUROPE PARIS

Mar 22 , 2020 Paris, France

CHINA FOCUS® @BIO

Jun 7, 2020 San Diego, U.S.

CHINA FOCUS® @JIANGSU

July, 2020 Jiangsu, China

CHINA FOCUS® @BWB

Sept 22-23, 2020 Boston, U.S.



CHINA FOCUS® @EUROPE MUNICH

Oct 25, 2020 Munich, Germany

CHINA FOCUS® @SAN FRANCISCO 2021

Jan 10, 2021 San Francisco, US

CONTACT US

WeChat: BiotoChina
E-mail: info@mybiogate.com
Web: https://events.mybiogate.com/sanfrancisco
https://chinafocus.mybiogate.com/sanfrancisco

ORGANIZER:

MYBIO 美柏医健 CUBIO INNOVATION CENTER